Women receiving MQ had reduced risks of parasitemia ( 63/1 ,372 [ 4.6 % ] in the SP group and 88/2 ,737 [ 3.2 % ] in the MQ group ; RR , 0.70 [ 95 % CI 0.51-0 .96 ] ; p = 0.03 ) and anemia at delivery ( 609/1 ,380 [ 44.1 % ] in the SP group and 1,110 / 2743 [ 40.5 % ] in the MQ group ; RR , 0.92 [ 95 % CI 0.85-0 .99 ] ; p = 0.03 ) , and reduced incidence of clinical malaria ( 96/551 .8 malaria episodes person/year [ PYAR ] in the SP group and 130/1 ,103.2 episodes PYAR in the MQ group ; RR , 0.67 [ 95 % CI 0.52-0 .88 ] ; p = 0.004 ) and all-cause outpatient attendances during pregnancy ( 850/557 .8 outpatients visits PYAR in the SP group and 1,480 / 1,110.1 visits PYAR in the MQ group ; RR , 0.86 [ 0.78-0 .95 ] ; p = 0.003 ) .